Market Overview - On July 24, stocks related to Hainan and duty-free concepts experienced significant gains, with multiple companies hitting the daily limit, including Caesar Travel, Haixia Co., China Duty Free Group, and others [1] - The Hainan Free Trade Port index rose by 8.81% [2] Event: Hainan's Customs Closure Launch - The Hainan Free Trade Port will officially start its customs closure on December 18, 2025, establishing the entire island as a special customs supervision area [3] - New policies will be implemented upon the closure, including an increase in the proportion of "zero tariff" goods from 21% to 74% [3] Institutional Analysis - The coverage of "zero tariff" goods will expand significantly from 1,900 to approximately 6,600 items, representing a 53 percentage point increase [4] - The beneficiaries of the "zero tariff" policy will now include various enterprises and non-profit organizations with actual import needs, broadening the scope of the policy [4] - Restrictions on the flow of imported "zero tariff" goods will be relaxed, allowing free movement among beneficiaries, which is expected to enhance the competitiveness of local industries [4] - The efficient management model and diverse consumer market in Hainan are anticipated to boost tourism, with the tourism industry expected to benefit from policy incentives [4] - The demand for professional tour guide services and one-stop solutions for international tourists is expected to rise, benefiting travel agencies involved in cross-border tourism [5] - The independent nature of the duty-free policy is likely to remain, with expectations of increased consumption post-closure, aiming for over 60 billion yuan in sales by 2027 [5]

Group 1 - The core viewpoint is that the Hainan Free Trade Zone is set to officially launch its customs closure on December 18, 2025, which is expected to significantly enhance the region's tourism and retail market [1][2] - The announcement led to a strong market response, with companies like Kangzhi Pharmaceutical hitting a 20% limit up, and others such as Hainan Airport and Haixia Co. also reaching their limit up [1] - The customs closure will create a special customs supervision area across Hainan Island, implementing a policy characterized by "freeing up the first line, controlling the second line, and allowing freedom within the island" [1] Group 2 - The continued implementation of the offshore duty-free policy is expected to maintain the competitive advantage of duty-free operators, as it offers more relaxed limits for consumers entering the "second line" [2] - The closure is anticipated to enhance Hainan's attractiveness, increase the flow of people, and promote the overall development of the tourism retail market [2] - Companies that have established a leading advantage in core property layout, supply chain resources, and operational capabilities are likely to maintain their competitive position in Hainan's retail market under the new policies [2]

Core Viewpoint - The announcement of the specific date for the closure of Hainan Free Trade Port on December 18, 2025, has led to a significant rise in local stocks, particularly in the tourism and retail sectors, indicating strong market optimism about the future economic benefits of the policy [1][2]. Group 1: Stock Performance - Hainan local stocks have seen substantial increases, with Kangzhi Pharmaceutical reaching a 20% limit up, and other companies like HNA Holding and Haixia Co. also experiencing significant gains [1][2]. - The stock performance of various companies includes: - Kangzhi Pharmaceutical: +20.00% - HNA Holding: +10.14% - Hainan Airport: +10.11% - Haide Co.: +10.08% - Hainan Expressway: +10.01% - Hainan Bus Group: +10.01% - Haixia Co.: +49.99% - Caesar Travel: +9.98% - Haima Automobile: +7.61% - Shennong Seed Industry: +7.68% [2]. Group 2: Policy Details - The closure policy includes four key measures: 1. Implementation of a more favorable "zero tariff" policy, increasing the proportion of zero-tariff goods from 21% to 74% for "first-line" imports, allowing tax-free circulation among eligible entities within the island [3][4]. 2. More relaxed trade management measures, opening up certain previously restricted imports [3]. 3. Enhanced convenience in transportation, with eight existing open ports designated as "first-line" ports and ten additional "second-line" ports for smoother import processes [3]. 4. A more efficient and precise regulatory model to ensure smooth implementation of the open policies [3]. Group 3: Industry Implications - The closure is expected to significantly benefit the tourism industry in Hainan, helping to establish it as an international tourism consumption center, with long-term advantages for related businesses such as scenic spots, hotels, and travel retailers [4]. - The continued implementation of duty-free policies will maintain the competitive edge of duty-free operators, while the increased attractiveness of Hainan is anticipated to boost the overall development of the tourism retail market [4]. - The efficient management model and diverse consumer market in Hainan are projected to enhance its tourism appeal, driving growth in inbound tourism [4].

Group 1 - Duty-free shops and Hainan Free Trade Zone sectors continue to rise, with Kangzhi Pharmaceutical (300086) hitting a 20% limit up [1] - Hainan Airport (600515), Haixia Co., Ltd. (002320), and Caesar Travel (000796) also reached their daily limit up [1] - China Duty Free Group (601888) increased by over 7%, while Wangfujing (600859) rose by over 4% [1] Group 2 - Dark pool funds are flowing into these stocks [2]

Group 1 - The Hainan Free Trade Zone sector experienced significant gains, with notable stocks such as Caesar Travel (000796) hitting the daily limit up [1] - Kangzhi Pharmaceutical (300086) saw an increase of over 10%, indicating strong market interest [1] - Other companies that followed the upward trend include HNA Holding (600221), Jinpan Technology, Hainan Development (002163), Haide Shares (000567), and Shennong Seed Industry (300189) [1]

Core Viewpoint - The mosquito-repellent concept stocks continue to show strong performance, driven by the reported cases of Chikungunya fever in Foshan, with a total of 3,195 confirmed cases as of July 22, primarily concentrated in Shunde District [1] Group 1: Company Performance - Rainbow Group has achieved a consecutive two-day increase in stock price [1] - Kangzhi Pharmaceutical has seen a rise of over 10% in its stock price [1] - Other companies such as Runben Co., Wanfang Biological, Shanghai Jahwa, Qingsong Co., and Lafang Co. have also experienced stock price increases [1]

Group 1 - The outbreak of Chikungunya fever in Shunde District, Foshan, has reported a total of 2,934 confirmed cases as of July 22, 2025, with a significant increase of 463 cases in one day [1] - The World Health Organization (WHO) has indicated that 119 countries and regions have reported Chikungunya virus transmission, affecting approximately 5.5 million people at risk, potentially leading to widespread outbreaks [1][2] - The spread of Chikungunya fever is primarily through mosquito bites, with no direct human-to-human transmission, making it crucial to implement effective mosquito control measures to prevent further outbreaks [2] Group 2 - Companies in the relevant sectors are expected to gain market attention due to the ongoing outbreak [2] - Novogene's official WeChat account highlighted the challenges in detecting mosquito-borne viruses early due to low viral loads and complex samples, which affects testing efficiency [2] - Kangzhi Pharmaceutical has a subsidiary, Zhongshan Aihu, that offers a full range of baby and child care products, including disinfectants and mosquito repellent products [3]

Group 1 - The local stocks in Hainan showed strength on July 22, with companies like Zhongtung High-tech and Caesar Travel reaching their daily limit up, while Haide Co., Kangzhi Pharmaceutical, and Hainan Development also saw gains [1] - On July 21, the People's Bank of China and five other departments issued the implementation details for the cross-border asset management pilot in Hainan Free Trade Port, allowing foreign investors to invest in various financial products with an initial pilot scale cap of 10 billion [6] - The State Council Information Office will hold a press conference on July 23, 2025, to discuss the construction of Hainan Free Trade Port, featuring key officials from various ministries [6] Group 2 - The cross-border asset management business in Hainan Free Trade Port is expected to enrich the supply of cross-border financial products and attract asset management institutions to operate in Hainan, aiding the development of the free trade port [8] - Hainan aims to start full island closure operations by the end of 2025, positioning itself to align with international standards similar to Hong Kong, which may enhance its global trade competitiveness [7][8] - The independent nature of the offshore duty-free policy in Hainan is anticipated to remain, with expected benefits from consumption-boosting policies post-closure, including an increase in the variety and quantity of duty-free products [8]

Group 1: Product Overview - The company produces over 50 types of medicines, with more than 100 specifications, of which over 30 are pediatric drugs, covering the highest proportion of respiratory, digestive, anti-allergy, antibiotic, and nutritional supplements for children [1] - Pediatric drugs account for approximately 70% of the company's product mix, while adult drugs, including gynecological products, make up about 30% [1] Group 2: Market Potential - China's medical expenditure is expected to grow significantly, driven by increasing health awareness and a large base of approximately 250 million children aged 0-14, despite a declining birth rate [2] - The demand for pediatric medicines is stable, supported by parents' increasing focus on children's health, with certain segments like ADHD showing rising demand [2] Group 3: R&D Focus - The company has over 30 years of experience in pediatric drug R&D, continuously innovating in taste, dosage forms, and packaging to enhance competitiveness [2] - Future R&D will focus on pediatric medications, emphasizing dosage form innovation and expanding the pediatric population for existing drugs [4][5] Group 4: Sales Strategy - The company plans to enhance its sales channels, including increasing online sales and participating in national medical insurance negotiations [6] - The company is exploring acquisition opportunities primarily in the children's health sector, focusing on technology complementarity and channel synergy [7]

本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示：1、本次股东大会无增加、变更提案的情况。 2、本次股东大会以现场和网络投票相结合的方式召开。 证券代码：300086 证券简称：康芝药业 公告编号：2025-031 康芝药业股份有限公司 2024 年度股东大会决议公告 网络投票时间：2025 年 6 月 30 日。 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 6 月 30 日 上午 9:15-9:25，9:30-11:30，下午 13:00-15:00；通过深圳证券交易所互联网投票系统 投票的具体时间为：2025 年 6 月 30 日 9:15-15:00 期间的任意时间。 3、本次股东大会未出现否决议案的情形。 4、本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开情况 1、召开时间 现场会议召开时间：2025 年 6 月 30 日（星期一）下午 15:00 开始。 2、股权登记日：2025 年 6 月 25 日 3、现场会议召开地点：海口国家高新技术产业开发区药谷工业园药谷三路 6 号。 4、会议召集人：康芝药业股 ...